Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 381

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 381
---
 recurring basis:

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    December 31, 2024: 

    Cash equivalents 

    Treasury bills 
    $10,260  
    $10,260  
    $      -  
    $        - 
  
    Money market funds 
     10,328  
     10,328  
     -  
     - 
  
    Total cash equivalents 
    $20,588  
    $20,588  
    $-  
    $- 

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    December 31, 2023: 

    Cash equivalents 

    Money market fund 
    $35,162  
    $35,162  
    $       -  
    $      - 
  
    Total cash equivalents 
    $35,162  
    $35,162  
    $-  
    $- 

F-13

NOTE 6 – LEASE

In September 2021, the Company signed a lease with a third party for
office space in Boca Raton, Florida. The lease agreement has a 64-month term and commenced during the fourth quarter of 2021.

Below is a summary of the Company’s right-of-use
assets and liabilities:

  (in thousands, except years and rate)  December 31, 2024   December 31, 2023   Right-of-use asset  $307   $414                Operating lease, current liability   140    119                Long-term operating lease liability   244    397   Total lease liability  $384   $516                Weighted-average remaining lease term   2.3 years    3.3 years                Weighted-average discount rate   12.0%   12.0% 

NOTE 7 –